Why Is Tempus AI Stock Gaining Thursday?
Key takeaways
- Positive melanoma trial results are lifting Tempus AI shares as investors weigh the strategic value of its planned Personalis acquisition.
- INTerpath‑001 Phase‑3 trial showed improved recurrence‑free survival
- TEM trading at $62, 26.6% above 20‑day SMA
- TEM 19.2% above 50‑day SMA
What happened
Tempus AI (NASDAQ: TEM) shares rose 1.22% to $62 in Thursday premarket trading, extending gains from the prior day. The rally is tied to a Phase‑3 cancer trial milestone that could boost the value of Tempus AI’s pending $1.5 billion acquisition of Personalis Inc.
Why it matters
The trial, INTerpath‑001, showed that a customized mRNA neo‑antigen therapy combined with Keytruda significantly improved recurrence‑free survival in resected melanoma patients— the first successful Phase‑3 readout for a personalized mRNA cancer treatment. Because Moderna uses Personalis’s sequencing platform to…
Short-term and longer-term
Short-term. Short‑term traders should watch the $63 resistance level; a break above could signal further upside, while a dip below $61.50 may trigger a pullback.
Longer-term. Over the next few weeks, investors should assess whether the positive trial results translate into a higher enterprise value for Personalis and whether the $1.5 billion acquisition can be financed without diluting…